| SANOFI PASTEUR Patent applications |
| Patent application number | Title | Published |
|---|
| 20120091026 | Method of Storing a Vaccine Containing an Aluminum Adjuvant - The invention relates to a method for loading and storing a vaccine composition, containing the antigen adsorbed on the aluminum adjuvant which (a) comprises (i) loading the composition into a container; and (ii) closing the container with a device in particular acting as a stopper, the surface of the device getting into contact with the composition being coated with a fluoropolymer such as Teflon™; and/or (b) loading the composition into a container wherein the inner surface of which is coated with polymerized silicone. The use of fluoropolymer or polymerized silicone optimizes the adsorbed antigen stability upon storage. In a particular embodiment, the antigen is the hepatitis B surface antigen and the aluminum adjuvant is aluminum oxy hydroxide. | 04-19-2012 |
| 20120044494 | METHOD FOR ESTIMATING THE AMOUNT OF ENTITIES DEPOSITED ON MICROPARTICLES IN SUSPENSION IN A SOLUTION, ASSOCIATED DEVICE AND USE OF SAID DEVICE - The invention relates to a method for estimating the amount of entities deposited on microparticles in suspension in a solution, and also to an associated device. The method comprises the following steps:
| 02-23-2012 |
| 20120003240 | Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (III) - Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic. | 01-05-2012 |
| 20120003239 | Enterovirus Vaccines for Preventing and Treating Type 1 Diabetes (II) - New enteroviruses associated with type 1 diabetes have been found, which opens up new therapeutic and diagnostic implications. A vaccine against at least one enterovirus selected from coxsackie A virus CAV4, CAV5, CAVE and echovirus 18 is provided for use in preventing or treating type 1 diabetes. A diagnostic assay for predicting the risk of contracting type 1 diabetes based on the determination of said enteroviruses is also provided. | 01-05-2012 |
| 20120003238 | Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (I) - Some coxsackie B viruses have been found to have a protective effect on type 1 diabetes, while others increase the risk of the disease. This opens up new therapeutic implications in the form of vaccines. The protective viruses CBV3, CBV4, CBV5 and CBV6 may be used in live attenuated vaccines for preventing or treating type 1 diabetes. They may also be used for inducing an immune response against risk viruses like CBV1, and for eliminating the diabetogenic effect of the risk viruses. Type 1 diabetes may be prevented especially by vaccinating with live attenuated protective viruses CBV3, CBV4, CVB5 and CBV6, and further with inactivated diabetogenic/risk virus CBV1, components thereof or antibodies thereto. | 01-05-2012 |
| 20110189226 | Immunization Compositions and Methods - The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus. | 08-04-2011 |
| 20110081380 | Stabilizing Excipient for Inactivated Whole Virus Vaccine - The invention relates to a vaccine composition comprising:
| 04-07-2011 |
| 20110014272 | Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria - The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of | 01-20-2011 |
| 20100330160 | Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6 - The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by | 12-30-2010 |
| 20100291192 | Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria - The invention relates to a method of detoxifying a lipopolysaccharide (LPS) or a lipid A from a Gram-negative bacterium, which comprises mixing the LPS or the lipid A with a cationic lipid so as to form a complex in which the LPS or the lipid A is associated with the cationic lipid. According to the conventional preparation modes, the cationic lipid with the co-lipid, if this latter is present, get(s) structured into complexes i.a. liposomes. When preparing lipidic complexes, the addition of LPS or Lipid A leads to an association of this latter with the cationic lipid and as a result, the LPS or lipid A is substantially detoxified. The LPS or lipid A detoxified by the complexes, e.g. when incorporated into liposomes, can be used as vaccinal antigen or as adjuvant. | 11-18-2010 |
| 20100260798 | Method for purifying the rabies virus - The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which:
| 10-14-2010 |
| 20100247557 | Immunostimulant Composition Comprising At Least One Toll-Like Receptor 7 Or Toll-Like Receptor 8 Agonist And A Toll-Like Receptor 4 Agonist - The invention relates to an immunostimulant composition comprising at least one Toll-like receptor 7 or Toll-like receptor 8 agonist and a receptor 4 agonist. The inventive composition can also comprise a vaccine antigen. | 09-30-2010 |
| 20100111990 | Polypeptide Recognized by Anti HIV-1 GP41 Antibodies Isolated from Highly HIV-1 Exposed, Non Infected Women - The invention relates to a polypeptide recognized by anti HIV-1 gp41 antibodies isolated from Highly Exposed, non Infected Women, and epitopic fragments and conjugate thereof. Method of inducing antibodies neutralizing HIV-1 against HIV-1 is also contemplated. | 05-06-2010 |
| 20100015180 | Stabilizer and Vaccine Composition Comprising One or More Live Attenuated Flaviviruses - The present invention relates to stabilizers for compositions, including immunogenic compositions, such as vaccine compositions, comprising one or more live attenuated flaviviruses, to bulk vaccine compositions stabilized with these stabilizers, particularly dry vaccine compositions prepared from these bulk vaccine compositions, and to methods for stabilizing one or more live attenuated flaviviruses. | 01-21-2010 |
| 20090232894 | Process for Stabilizing an Adjuvant Containing Vaccine Composition - The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form. | 09-17-2009 |
| 20090203881 | Polymyxin B Analogs for LPS Detoxification - The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and therefore to detoxify LPS as polymyxin B does. The dimeric structure is maintained by a pair of disulphide bonds involving the two cystein residues present in the peptide sequence, which does not exceed 17 amino acids and essentially comprises cationic and hydrophobic amino acid residues. In the dimers of the invention, peptides may have a parallel or anti-parallel orientation. As a matter of example, a dimer of the invention is constituted by a peptide of formula NH2-Lys-Thr-Lys-Cys1-Lys-Phe-Leu-Leu-Leu-Cys2-COOH, either in a parallel or antiparallel dimeric form. SAEP II dimers are useful for treating or preventing septic shock and related disorders generated by Gram-negative bacteria infection. The invention also relates to LPS-peptide complexes in which LPS and SAEP II dimers are non-covalently bound together. These complexes are useful as vaccinal agents against Gram-negative bacteria infection. | 08-13-2009 |
| 20090104227 | VACCINE COMPOSITION FOR THE PREVENTION OF CMV INFECTION - The invention relates to a method for preventing HCMV infection in HCMV seronegative human subjects and for preventing HCMV congenital infection in newborns, which method comprises administering an effective amount of a vaccine composition containing the gB antigen of HCMV in an O/W emulsion to the seronegative human subjects. | 04-23-2009 |
| 20090092620 | FLU VIRUS HEMAGGLUTININ SPECIFIC MONOCLONAL ANTIBODIES - The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group. | 04-09-2009 |
| 20090081255 | Method for Producing the Flu Virus - The invention relates to a method for producing flu virus according to which:
| 03-26-2009 |
